PRED G SUMMARY
PRED-G® sterile ophthalmic suspension is a topical anti-inflammatory/anti-infective combination product for ophthalmic use.
PRED-G® suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.
Published Studies Related to Pred G (Gentamicin / Prednisolone Ophthalmic)
Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space. [2007.05]
PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery. SETTING: St. Luke's Hospital, Gwardamangia, Malta... CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache. All adverse effects were self-limiting.
Clinical Trials Related to Pred G (Gentamicin / Prednisolone Ophthalmic)
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach [Recruiting]
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with
polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose
glucocorticoids ( 5 mg/day of prednisone) as compared to stopping glucocorticoid treatment
entirely (0 mg/day of prednisone)on rates of disease relapse/disease flares.
This study is a novel approach to conducting a randomized clinical trial in the community
setting. This study is being conducted in parallel with a similar study at established
vasculitis institutions. This study will have a patient centric approach to research in
that subjects will be recruited online and through social media and vasculitis support
networks. Participants will be consented online and will receive care through their regular
treating physician so no travel or additional doctor visits are required. Study participants
will consent to the study and complete online questionnaires about their prednisone dose and
about how they are feeling.
Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant [Terminated]
The purpose of the study was to determine if rapid discontinuation of corticosteroids (also
known as prednisone withdrawal) and maintenance immunosuppression with Prograf (tacrolimus)
and CellCept (mycophenolate mofetil) while using Thymoglobulin (Rabbit antithymocyte
globulin) will give similar safety and efficacy results compared to continuation of
corticosteroids (also known as prednisone maintenance) and standard maintenance
immunosuppression with Prograf (tacrolimus), CellCept (mycophenolate mofetil) while using
Thymoglobulin (Rabbit antithymocyte globulin).
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone [Recruiting]
Tuberculosis (TB) is the most common opportunistic infection amongst HIV-infected patients
starting antiretroviral therapy (ART) in developing countries and thus the most frequent
form of immune reconstitution inflammatory syndrome (IRIS). Paradoxical TB-IRIS occurs in 8-
43% of patients starting ART while on TB treatment and results in morbidity,
hospitalisation, consumes health care resources and TB-IRIS may be fatal. We have previously
demonstrated in a clinical trial that prednisone reduces morbidity when used for treatment
of paradoxical TB-IRIS. This trial is a double-blind placebo-controlled trial of
prophylactic prednisone (40mg/day for 2 weeks followed by 20mg/day for 2 weeks, started on
the same day as ART) in patients with TB who are identified as being at high risk for
paradoxical TB-IRIS (starting ART within 30 days of initiating TB treatment and CD4 <
100/μL). The trial will enroll 240 participants, randomised 1: 1 (prednisone: placebo). The
primary endpoint is development of paradoxical TB-IRIS, defined using international
consensus case definitions. Secondary endpoints include time to IRIS event, severity of
IRIS, quality of life assessment, mortality and corticosteroids adverse events. The trial is
powered to determine a reduction in TB-IRIS events.
Dose-comparison Study of Prednisone in Heart Failure [Completed]
The purpose of this study is to examine the efficacy of three doses of prednisone, a
glucocorticoid, in treatment of patients with symptomatic heart failure.
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach [Recruiting]
This study is a multi-center randomized controlled trial to evaluate the effects of using
low-dose prednisone as compared to stopping prednisone treatment entirely. Participants will
be randomized 1: 1 to taper their prednisone dose down to 5 mg/day or to 0 mg/day for the
duration of the study (approximately six months) or until a study endpoint.
Page last updated: 2007-08-04